Powering a prospective melanoma chemoprevention trial in high-risk cohorts

doi:10.1111/ijd.14538

Review

. 2019 Nov;58(11):e232-e234.

doi: 10.1111/ijd.14538. Epub 2019 Jun 17.

Powering a prospective melanoma chemoprevention trial in high-risk cohorts

Amir Varedi¹, Michael D Bishop¹, Kenneth M Boucher^{1

2}, Caroline C Kim³, Douglas Grossman^{1

4

5}

Affiliations

¹ Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
² Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
³ Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
⁴ Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA.
⁵ Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA.

PMID: 31206619
PMCID: PMC7140151
DOI: 10.1111/ijd.14538

Review

Powering a prospective melanoma chemoprevention trial in high-risk cohorts

Amir Varedi et al. Int J Dermatol. 2019 Nov.

. 2019 Nov;58(11):e232-e234.

doi: 10.1111/ijd.14538. Epub 2019 Jun 17.

Authors

Amir Varedi¹, Michael D Bishop¹, Kenneth M Boucher^{1

2}, Caroline C Kim³, Douglas Grossman^{1

4

5}

Affiliations

¹ Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, USA.
² Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
³ Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
⁴ Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA.
⁵ Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA.

PMID: 31206619
PMCID: PMC7140151
DOI: 10.1111/ijd.14538

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have no conflicts of interest to declare.

Cited by

Low accuracy of self-reported family history of melanoma in high-risk patients.
Flint ND, Bishop MD, Smart TC, Strunck JL, Boucher KM, Grossman D, Secrest AM. Flint ND, et al. Fam Cancer. 2021 Jan;20(1):41-48. doi: 10.1007/s10689-020-00187-0. Fam Cancer. 2021. PMID: 32436000 Review.

References

1. Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29: 257–263. - PubMed
1. Jeter JM, Bowles TL, Curiei-Lewandrowski C, et al. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials. Cancer 2018; 125: 18–44. - PMC - PubMed
1. Banky JP, Kelly JW, English DR, et al. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005; 141: 998–1006. - PubMed
1. Halpern AC, Guerry D, Elder DE, et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993; 100: 346S–349S. - PubMed
1. Moloney FJ, Guitera P, Coates E, et al. Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study. JAMA Dermatol 2014; 150: 819–827. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

R21 AR056797/AR/NIAMS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29: 257–263. - PubMed

[2] Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29: 257–263. - PubMed

[3] Jeter JM, Bowles TL, Curiei-Lewandrowski C, et al. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials. Cancer 2018; 125: 18–44. - PMC - PubMed

[4] Jeter JM, Bowles TL, Curiei-Lewandrowski C, et al. Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials. Cancer 2018; 125: 18–44. - PMC - PubMed

[5] Banky JP, Kelly JW, English DR, et al. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005; 141: 998–1006. - PubMed

[6] Banky JP, Kelly JW, English DR, et al. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch Dermatol 2005; 141: 998–1006. - PubMed

[7] Halpern AC, Guerry D, Elder DE, et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993; 100: 346S–349S. - PubMed

[8] Halpern AC, Guerry D, Elder DE, et al. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993; 100: 346S–349S. - PubMed

[9] Moloney FJ, Guitera P, Coates E, et al. Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study. JAMA Dermatol 2014; 150: 819–827. - PubMed

[10] Moloney FJ, Guitera P, Coates E, et al. Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study. JAMA Dermatol 2014; 150: 819–827. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Powering a prospective melanoma chemoprevention trial in high-risk cohorts

Affiliations

Powering a prospective melanoma chemoprevention trial in high-risk cohorts

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical